Groupama Asset Managment Purchases 32,162 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)

Groupama Asset Managment grew its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 41.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 110,207 shares of the company's stock after acquiring an additional 32,162 shares during the period. Groupama Asset Managment owned about 0.08% of Denali Therapeutics worth $2,231,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. PNC Financial Services Group Inc. raised its position in shares of Denali Therapeutics by 30.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock worth $77,000 after purchasing an additional 885 shares during the period. KBC Group NV boosted its holdings in shares of Denali Therapeutics by 75.8% during the fourth quarter. KBC Group NV now owns 6,334 shares of the company's stock valued at $129,000 after acquiring an additional 2,731 shares during the period. AlphaQuest LLC grew its position in shares of Denali Therapeutics by 177.1% during the fourth quarter. AlphaQuest LLC now owns 6,961 shares of the company's stock worth $142,000 after acquiring an additional 4,449 shares during the last quarter. E Fund Management Co. Ltd. increased its holdings in shares of Denali Therapeutics by 32.2% in the 4th quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company's stock worth $204,000 after acquiring an additional 2,436 shares during the period. Finally, SG Americas Securities LLC increased its holdings in shares of Denali Therapeutics by 128.8% during the fourth quarter. SG Americas Securities LLC now owns 11,003 shares of the company's stock valued at $224,000 after purchasing an additional 6,195 shares during the period. Institutional investors own 92.92% of the company's stock.

Remove Ads

Insider Buying and Selling at Denali Therapeutics

In other news, Director Steve E. Krognes sold 3,339 shares of the firm's stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $20.81, for a total value of $69,484.59. Following the transaction, the director now directly owns 25,757 shares in the company, valued at $536,003.17. This trade represents a 11.48 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 7.90% of the company's stock.

Denali Therapeutics Stock Down 4.7 %

DNLI traded down $0.56 during midday trading on Monday, reaching $11.22. 714,020 shares of the company's stock were exchanged, compared to its average volume of 1,058,805. The firm has a market capitalization of $1.63 billion, a price-to-earnings ratio of -4.01 and a beta of 1.58. The business has a 50-day simple moving average of $18.06 and a two-hundred day simple moving average of $22.60. Denali Therapeutics Inc. has a one year low of $10.58 and a one year high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.08. As a group, research analysts anticipate that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on DNLI shares. Oppenheimer decreased their target price on shares of Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating for the company in a research report on Monday, March 3rd. Morgan Stanley assumed coverage on Denali Therapeutics in a report on Friday, March 7th. They set an "overweight" rating and a $33.00 price objective on the stock. JPMorgan Chase & Co. decreased their target price on shares of Denali Therapeutics from $28.00 to $24.00 and set an "overweight" rating for the company in a report on Tuesday, January 7th. Robert W. Baird initiated coverage on shares of Denali Therapeutics in a research report on Tuesday, January 7th. They issued an "outperform" rating and a $31.00 target price on the stock. Finally, William Blair reaffirmed an "outperform" rating on shares of Denali Therapeutics in a research note on Friday, February 28th. Two analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $37.20.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.